These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 1378887

  • 1. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
    Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A.
    J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
    [Abstract] [Full Text] [Related]

  • 2. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
    Bayouth JE, Macey DJ, Kasi LP, Fossella FV.
    J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
    Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA.
    J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
    [Abstract] [Full Text] [Related]

  • 4. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Liepe K, Runge R, Kotzerke J.
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
    Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ.
    Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F.
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W, Kampen WU, Kampen AM, Henze E.
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [Abstract] [Full Text] [Related]

  • 14. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
    Etchebehere EC, Pereira Neto CA, Lima MC, Santos Ade O, Ramos CD, Silva CM, Camargo EE.
    Sao Paulo Med J; 2004 Sep 02; 122(5):208-12. PubMed ID: 15558143
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J, Vizd'a J, Cermáková E.
    Vnitr Lek; 2003 Mar 02; 49(3):189-93. PubMed ID: 12728593
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.